Pepper Bio Presenting Transomic Platform Analysis at BIO International Convention

Boston, Mass. (May 11, 2023) – Pepper Bio, the world’s first transomics drug discovery company, announced today that co-founder and Chief Science Officer Samantha Dale Strasser, Ph.D., will be presenting at the BIO International Convention.

In a presentation titled ’Selecting Successful Drugs via Transomics’, Dr. Strasser will share findings from Pepper Bio’s bioplatform’s analysis of approved and unapproved EGFR TK inhibitors (EGFRi) for non-small cell lung cancer (NSCLC) on Wednesday, June 7, at 4:15 PM Room 104A.

“Through our work, we’ve established that transomic analysis identifies critical differences between successful drugs and drugs that failed in clinical development,” said Dr. Strasser. “The implications this has for drug discovery R&D are immense, providing an avenue to alleviate uncertainty around drug candidates and shift incentives so that investment goes toward more challenging diseases.”

Pepper Bio’s COMPASS platform integrates genomic, transcriptomic, proteomic, and phosphoproteomic data to interpret complex biological relationships and provide a functional map of the biochemical drivers of disease. By incorporating these layers of data, the platform is able to capture the full complexity of biology and drive towards a global, functional, and causal understanding.

With the goal of driving novel drug discovery to circumvent resistance to EGFR-targeted drugs, Pepper Bio used COMPASS to evaluate five third generation EGFRi and identify key mechanisms that drive efficacy, or lack thereof, of EGFRi in NSCLC. The subsequent transomic analysis detected dramatic differences between approved and unapproved drugs with the same mechanism of action.

“Importantly, this study highlights that transomic analysis can identify potential challenges early in the drug discovery process, allowing the best candidates to be selected before costly clinical trials,” said Chris Nicholson, Ph.D., Head of Biology at Pepper Bio and lead author on the study. “At BIO, we look forward to sharing these findings, which are indicative of the work we’re accomplishing with top biotech companies and academic institutions.”

This presentation comes on the heels of Pepper Bio’s participation in the inaugural Merck Digital Sciences Studio (MDSS) cohort and the commencement of a partnership with a top five global pharmaceutical company.

This year, Pepper Bio has also leveraged its technology in ongoing collaboration with Stanford’s Felsher Lab to identify and validate novel therapeutic targets for hepatocellular carcinoma and lymphoma. Additionally, COMPASS has supported clinical stage compound characterization through a commercial partnership with a top CNS-focused pharma company.

Dr. Strasser and the Pepper Bio team will be available to answer questions about the platform, discuss partnership opportunities, and share more about upcoming announcements. To connect with Dr. Strasser at BIO, please reach out to: samantha@pepper.bio.

To learn more about Pepper Bio’s platform, please visit: https://intro.pepper.bio/.

About Pepper Bio

Pepper Bio is the world’s first transomics drug discovery company, leveraging its proprietary transomics database and analytics to identify promising first-in-class therapies, rediscover new uses for existing therapeutics, and rescue drugs in development on a path toward failure. Founded in 2020 and based in Boston, Massachusetts, Pepper Bio is led by co-founder and Chief Executive Officer, Jon Hu, and co-founder and Chief Science Officer, Samantha Dale Strasser, Ph.D. To learn more about Pepper, please visit: http://pepper.bio.

##

Contact Information

Melissa Mowery

Account Manager

VSC for Pepper Bio

pepperbio@vsc.co